Prolor Biotech to Present at The Rodman & Renshaw Sixth Annual Global Healthcare Conference

NES-ZIONA, Israel, May 11 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that PROLOR's management will give a corporate presentation at the Rodman & Renshaw Sixth Annual Global Healthcare Conference, to be held at the Grosvenor House Hotel in London, U.K.  The presentation is scheduled for May 18, 2010 at 12:45 pm local time  (7:45 am ET).

A live webcast of the company's presentation will be available in the Investors section of PROLOR's website at http://www.prolor-biotech.com/?CategoryID=215, or at the Rodman & Renshaw website at http://www.wsw.com/webcast/rrshq17/pbth.  A replay will be available on the PROLOR website and will be archived for at least 30 days.

For more information on the conference, visit http://www.rodm.com/conferences?id=44    

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins and PROLOR is currently developing long-acting versions of human growth hormone, which is in clinical development, and interferon beta, factor VII, factor IX and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide.  For more information on PROLOR, visit www.prolor-biotech.com.

PROLOR CONTACT:

MEDIA CONTACT:

Shai Novik, President

Barbara Lindheim

PROLOR Biotech, Inc.

GendeLLindheim BioCom Partners

Tel: +1-866-644-7811

+1-212-918-4650

Email: [email protected]




SOURCE PROLOR Biotech, Inc.

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.